Fig. 1

Study design. A Female Wistar rats received from nine daily topical administrations of imiquimod (IMQ) or vehicle (Vaseline^®). Test antibodies or vehicle formulations were administered on Day 1, 3, and Day 6. Development of psoriasis-like dermatitis B appeared starting Day 4 continuing through Day 10. On Day 10, severity of the back inflammation was monitored on a modified clinical Psoriasis Area and Severity Index (PASI) scoring system. Scratching behavior was captured by videotape and serum and back skin samples were collected for cytokine measurements and immunohistochemistry to visualize IMQ induced morphological changes. Number of scratching bouts in IMQ-treated rats was significantly (P < 0.0001) higher than animals exposed to vehicle in C female Wistar rats and D F2RL1 knockin female Wistar rat animals from various studies under control conditions (n = 15 total). Data is expressed as the mean (SEM). Asterisk (*) denotes P values of IMQ compared to vehicle, *P < 0.0001 (Student’s t-test, followed by Mann–Whitney post-test)